Chronic respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis are increasingly recognized as heterogeneous disorders driven by underlying immune processes [1]. A key discovery in modern pulmonology is the role of type 2 inflammation, which serves as a common biological denominator across several chronic airway diseases [1]. By utilizing molecular and cellular endotyping, clinicians can look beyond broad symptom categories to target the specific drivers of a patient's condition [1]. Biomarkers such as blood eosinophils, fractional exhaled nitric oxide (FeNO), and immunoglobulin E (IgE) help guide these personalized medical decisions, offering insights into disease progression and treatment response [1].
Targeted Biologics and Precision Therapies
The shift toward precision medicine has introduced biologic therapies designed to neutralize specific inflammatory pathways. For instance, biologics targeting interleukins like IL-4, IL-13, and IL-5, as well as upstream alarmins, have shown significant clinical potential in carefully selected patient populations [1]. Recent clinical trials, such as the BOREAS and NOTUS studies, highlight the success of agents like dupilumab in addressing type 2 inflammatory pathways in eosinophilic COPD, improving lung function and reducing exacerbations [7]. Similarly, randomized trials have examined the use of benralizumab for acute eosinophilic exacerbations [2], while other biologic studies continue to evaluate targeted options for severe asthma [2, 5].
Novel Inhaled Medications and Dual-Action Drugs
Beyond injectables, new pharmacological approaches are expanding outpatient treatment options for chronic lung disease [3]. Ensifentrine, an inhaled therapy recently approved for COPD maintenance, features a dual mechanism of action by inhibiting both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) [4]. This combination delivers both bronchodilator and anti-inflammatory benefits, effectively filling an existing treatment gap for patients who continue to experience persistent symptoms despite standard guideline-based therapies [4]. These dual-action agents represent an important step forward in managing progressive airflow limitation and chronic airway inflammation [4, 7].
Non-Pharmacological Care and Lifestyle Interventions
Effective management of pulmonary inflammation extends well beyond medications. Non-pharmacological strategies—such as optimized breathing techniques, long-term oxygen therapy management, and structured pulmonary rehabilitation—play a critical role in patient outcomes [2, 8]. Furthermore, combined lifestyle interventions focusing on diet, regular physical activity, and smoking cessation have been shown to improve exercise capacity, reduce respiratory symptoms, and enhance overall quality of life for individuals with asthma and COPD [6]. Integrated care also addresses the psychological burden of chronic lung disease, utilizing cognitive behavioral therapy and self-management programs to alleviate anxiety and depression [8].
Sources
- [1] Type 2 inflammation, a common denominator in chronic airway disease? PubMed
- [2] Pulmonology: What You May Have Missed in 2024. PubMed
- [3] New Therapies in Outpatient Pulmonary Medicine. PubMed
- [4] Ensifentrine: a novel approach to redefining COPD management and implications for additional respiratory diseases. PubMed
- [5] Pulmonology: What You May Have Missed in 2025. PubMed
- [6] Combined Lifestyle Interventions in the Prevention and Management of Asthma and COPD: A Systematic Review. PubMed
- [7] Advancing COPD management through novel pharmacological agents: ensifentrine and dupilumab. PubMed
- [8] Toward Holistic COPD Management: The Case for Mental Health Integration. PubMed